High performance plasma amyloid-β biomarkers for Alzheimer’s disease

Akinori Nakamura, Naoki Kaneko, Victor L. Villemagne, Takashi Kato, James Doecke, Vincent Doré, Chris Fowler, Qiao-Xin Li, Ralph Martins, Christopher Rowe, Taisuke Tomita, Katsumi Matsuzaki, Kenji Ishii, Kazunari Ishii, Yutaka Arahata, Shinichi Iwamoto, Kengo Ito, Koichi Tanaka, Colin L. Masters and Katsuhiko Yanagisawa ()
Additional contact information
Akinori Nakamura: Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology
Naoki Kaneko: Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation
Victor L. Villemagne: Austin Health, Center for PET, Heidelberg
Takashi Kato: Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology
James Doecke: Health and Biosecurity, CSIRO
Vincent Doré: Austin Health, Center for PET, Heidelberg
Chris Fowler: The Florey Institute, The University of Melbourne
Qiao-Xin Li: The Florey Institute, The University of Melbourne
Ralph Martins: Edith Cowan University
Christopher Rowe: Austin Health, Center for PET, Heidelberg
Taisuke Tomita: Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo
Katsumi Matsuzaki: Graduate School of Pharmaceutical Sciences, Kyoto University
Kenji Ishii: Team for Neuroimaging Research, Tokyo Metropolitan Institute of Gerontology
Kazunari Ishii: Kindai University Faculty of Medicine, Osakasayama
Yutaka Arahata: National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology
Shinichi Iwamoto: Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation
Kengo Ito: Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology
Koichi Tanaka: Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation
Colin L. Masters: The Florey Institute, The University of Melbourne
Katsuhiko Yanagisawa: Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology

Nature, 2018, vol. 554, issue 7691, 249-254

Abstract: Measurement of human plasma amyloid-β biomarkers using immunoprecipitation coupled with mass spectrometry reliably predicts individual brain amyloid-β status and has potential clinical utility.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/nature25456 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:554:y:2018:i:7691:d:10.1038_nature25456

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature25456

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().